Drugs / U96
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07511426 | Jul 2026 → Jan 2027 expected | lymphoid neoplasm | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U96 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511426 ↗ |
| Action | Inhibit | “IL-6 knockdown” NCT07511426 ↗ |
| Route | Intravenous | “Intravenous injection” NCT07511426 ↗ |
| Target | CD19 | “IL-6 knockdown CD19 CAR” NCT07511426 ↗ |
| Target | CD7 | “CD7-targeted lentiviral vector” NCT07511426 ↗ |